Adaptimmune Therapeutics plc (ADAP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Adaptimmune Therapeutics plc (ADAP) with AI Score 46/100 (Weak). Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel cell therapies for solid tumors. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Adaptimmune Therapeutics plc (ADAP) Healthcare & Pipeline Overview
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumors, utilizing its SPEAR T-cell platform to target cancer. With multiple therapies in clinical trials, the company focuses on addressing unmet needs in oncology within the competitive biotechnology landscape.
Investment Thesis
Adaptimmune Therapeutics presents a high-risk, high-reward investment opportunity within the cell therapy space. The company's SPEAR T-cell platform holds promise in addressing solid tumors, with ADP-A2M4 showing potential in Phase II trials for synovial sarcoma and MRCLS. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's collaborations with GSK and Genentech validate its technology and provide financial resources. However, the company's negative profit margin of -260.8% and reliance on clinical trial success pose significant risks. Investors should closely monitor clinical trial data, regulatory milestones, and competitive developments in the cell therapy landscape. Adaptimmune's high beta of 2.49 indicates significant volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.08 billion reflects the company's early stage and risk profile.
- Gross margin of 94.8% indicates strong potential profitability upon commercialization of products.
- P/E ratio of -0.01 reflects the company's current lack of profitability due to ongoing clinical trials and R&D expenses.
- The company's focus on solid tumors addresses a significant unmet medical need in oncology.
- Collaborations with major pharmaceutical companies like GSK and Genentech validate Adaptimmune's technology and provide financial support.
Competitors & Peers
Strengths
- Proprietary SPEAR T-cell platform.
- Strong intellectual property portfolio.
- Strategic collaborations with major pharmaceutical companies.
- Focus on addressing unmet medical needs in oncology.
Weaknesses
- Clinical-stage company with no currently approved products.
- High R&D costs and long development timelines.
- Reliance on clinical trial success.
- Negative profit margin.
Catalysts
- Data readouts from ongoing Phase II clinical trials for ADP-A2M4 in synovial sarcoma and MRCLS (SPEARHEAD-1) and head and neck cancer (SPEARHEAD-2) expected in late 2026.
- Advancement of ADP-A2AFP into Phase II clinical trials for hepatocellular carcinoma anticipated in 2027, pending Phase I results.
- Strategic collaborations with GSK and Genentech provide financial resources and potential for co-development and commercialization of therapies.
- Expansion of the SPEAR T-cell platform to new cancer targets and indications.
Risks
- Unfavorable clinical trial results could delay or halt the development of Adaptimmune's therapies.
- Regulatory hurdles and potential delays in approvals could impact the timeline for commercialization.
- Competition from other biotechnology and pharmaceutical companies developing cancer therapies.
- Reliance on strategic partnerships for funding and expertise.
- Patent expiration and generic competition could erode market share.
Growth Opportunities
- Expansion of ADP-A2M4 into additional indications: Adaptimmune has the opportunity to expand the use of ADP-A2M4 beyond synovial sarcoma and MRCLS. The ongoing Phase I trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal, and gastric cancers represent significant growth opportunities. Success in these trials could significantly expand the addressable market for ADP-A2M4, potentially reaching billions of dollars. The timeline for this expansion depends on clinical trial results and regulatory approvals, but could begin to materialize within the next 3-5 years.
- Advancement of ADP-A2AFP for hepatocellular carcinoma: The development of ADP-A2AFP for hepatocellular carcinoma represents another significant growth opportunity. Hepatocellular carcinoma is a major unmet medical need, and successful development and commercialization of ADP-A2AFP could generate substantial revenue. The drug is currently in Phase I trials, with potential for advancement to later-stage trials in the next 2-3 years. The market for hepatocellular carcinoma therapies is estimated to be worth billions of dollars annually.
- Development of ADP-A2M4CD8 for various cancers: Adaptimmune's ADP-A2M4CD8 program, targeting lung, gastroesophageal, head and neck, ovarian, and bladder cancers, offers a broad growth opportunity. These cancers represent a significant portion of the overall oncology market. The drug is currently in Phase I trials, and positive results could lead to further development and commercialization. The timeline for this program is dependent on clinical trial outcomes, but could contribute to revenue growth within the next 5 years.
- Leveraging strategic partnerships for co-development and commercialization: Adaptimmune's collaborations with GSK, Genentech, and other companies provide access to resources and expertise that can accelerate the development and commercialization of its products. These partnerships can also provide financial support through milestone payments and royalties. By effectively leveraging these partnerships, Adaptimmune can maximize the value of its pipeline and expand its market reach. The impact of these partnerships will be ongoing as programs advance through clinical development.
- Expansion of the SPEAR T-cell platform to new targets: Adaptimmune's SPEAR T-cell platform is a versatile technology that can be applied to a wide range of cancer targets. By identifying and validating new targets, Adaptimmune can expand its pipeline and address additional unmet medical needs. This platform-based approach provides a sustainable source of innovation and growth. The timeline for this expansion is dependent on research and development efforts, but could lead to new product candidates within the next 3-5 years.
Opportunities
- Expansion of ADP-A2M4 into additional indications.
- Advancement of ADP-A2AFP for hepatocellular carcinoma.
- Development of ADP-A2M4CD8 for various cancers.
- Leveraging strategic partnerships for co-development and commercialization.
Threats
- Competition from other biotechnology and pharmaceutical companies.
- Regulatory hurdles and potential delays in approvals.
- Unfavorable clinical trial results.
- Patent expiration and generic competition.
Competitive Advantages
- Proprietary SPEAR T-cell platform technology.
- Strong intellectual property portfolio protecting its therapies.
- Strategic collaborations with major pharmaceutical companies.
- Expertise in cell therapy development and manufacturing.
About ADAP
Founded in 2008 and headquartered in Abingdon, United Kingdom, Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for cancer patients. The company's core technology is its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform, which enables the identification of cancer targets and the engineering of T-cells to recognize and destroy tumor cells. Adaptimmune's lead candidate, ADP-A2M4, is currently in Phase II clinical trials (SPEARHEAD-1) for synovial sarcoma and myxoid round cell liposarcoma (MRCLS). It is also in Phase II trials (SPEARHEAD-2) for head and neck cancer, and Phase I trials for various other cancers including urothelial, melanoma, ovarian, non-small cell lung, esophageal, and gastric cancers. Other pipeline assets include ADP-A2AFP for hepatocellular carcinoma and ADP-A2M4CD8 for lung, gastroesophageal, head and neck, ovarian, and bladder cancers, both in Phase I trials. Adaptimmune has established collaborations with GSK, Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., the National Center for Cancer Immune Therapy in Denmark, MD Anderson Cancer Center, Universal Cells, Inc., Genentech, Inc., and F. Hoffman-La Roche Ltd to further develop and commercialize its cell therapy products.
What They Do
- Develop novel cell therapies for solid tumors.
- Utilize the SPEAR T-cell platform to identify cancer targets.
- Engineer T-cells to recognize and destroy tumor cells.
- Conduct clinical trials to evaluate the safety and efficacy of its therapies.
- Collaborate with pharmaceutical companies to develop and commercialize its products.
- Focus on addressing unmet medical needs in oncology.
- Develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors.
Business Model
- Develops and patents novel cell therapies.
- Out-licenses or co-develops therapies with larger pharmaceutical companies.
- Generates revenue through milestone payments, royalties, and potential product sales.
- Focuses on research and development, with a long-term goal of commercializing its therapies.
Industry Context
Adaptimmune Therapeutics operates in the rapidly evolving biotechnology industry, specifically within the cell therapy market. This market is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The cell therapy market is projected to experience substantial growth, driven by advancements in immunotherapy and personalized medicine. Adaptimmune's SPEAR T-cell platform positions it to compete with companies like ANL, APLM, BLRX, ERNA, and GOVX, which are also developing novel cancer therapies. Success in this field depends on demonstrating clinical efficacy, securing regulatory approvals, and establishing strategic partnerships.
Key Customers
- Cancer patients with solid tumors.
- Hospitals and oncology clinics.
- Pharmaceutical companies through collaborations and licensing agreements.
Financials
Chart & Info
Adaptimmune Therapeutics plc (ADAP) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
· Oct 2, 2019
-
New 52-Week Lows For Monday Morning
· Aug 5, 2019
-
Stocks That Set New 52-Week Lows Friday Morning
· Aug 2, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADAP.
Price Targets
Wall Street price target analysis for ADAP.
MoonshotScore
What does this score mean?
The MoonshotScore rates ADAP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Adrian G. Rawcliffe
Chief Executive Officer
Adrian G. Rawcliffe serves as the Chief Executive Officer of Adaptimmune Therapeutics. His career spans leadership roles in the biotechnology and pharmaceutical sectors. Prior to Adaptimmune, he held significant positions at companies focused on oncology and cell therapy development. His experience includes strategic planning, business development, and commercialization of innovative therapies. He brings a wealth of knowledge in navigating the complexities of the biopharmaceutical industry.
Track Record: Under Adrian Rawcliffe's leadership, Adaptimmune has focused on advancing its SPEAR T-cell platform and expanding its clinical pipeline. He has overseen the progression of ADP-A2M4 through Phase II clinical trials and has secured strategic collaborations with major pharmaceutical companies like GSK and Genentech. These partnerships have provided financial resources and validation for Adaptimmune's technology.
Adaptimmune Therapeutics plc ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For Adaptimmune Therapeutics (ADAP), each ADR represents a specific number of ordinary shares of the company traded on its home market. This allows U.S. investors to easily invest in Adaptimmune without dealing with foreign exchanges.
- Home Market Ticker: London Stock Exchange (LSE), United Kingdom
- ADR Level: 2
- ADR Ratio: 1:1
ADAP Healthcare Stock FAQ
What does Adaptimmune Therapeutics plc do?
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel cell therapies for the treatment of solid tumors. The company's core technology is its SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform, which enables it to identify cancer targets and engineer T-cells to recognize and destroy tumor cells. Adaptimmune's lead product candidate, ADP-A2M4, is currently in Phase II clinical trials for synovial sarcoma and myxoid round cell liposarcoma (MRCLS), with additional programs targeting other solid tumors. They aim to provide effective treatments for cancers with limited options.
What do analysts say about ADAP stock?
Analyst coverage of Adaptimmune Therapeutics plc (ADAP) is currently limited, reflecting the company's clinical-stage status and inherent risks associated with biotechnology investments. Key valuation metrics are difficult to assess due to the company's lack of current revenue and profitability. However, analysts generally focus on the potential of Adaptimmune's SPEAR T-cell platform and the progress of its clinical trials. Positive clinical trial data and regulatory milestones are expected to drive future stock performance. Investors should conduct their own due diligence and consider the risks before investing.
What are the main risks for ADAP?
Adaptimmune Therapeutics plc faces several key risks inherent to its business model and the biotechnology industry. Clinical trial risk is paramount, as unfavorable results could significantly impact the company's pipeline and valuation. Regulatory risks are also significant, as delays or denials of approval could hinder commercialization efforts. Competition from other biotechnology and pharmaceutical companies developing cancer therapies poses a constant threat. Financial risks include the need to raise additional capital to fund ongoing research and development activities. Patent protection and intellectual property rights are also crucial to the company's long-term success.
How does Adaptimmune Therapeutics plc navigate regulatory approval processes?
Adaptimmune Therapeutics plc navigates the complex regulatory approval processes by working closely with regulatory agencies such as the FDA and EMA. The company designs its clinical trials to meet regulatory requirements and provides comprehensive data packages to support its applications. They also engage in ongoing dialogue with regulatory agencies to address any concerns and ensure compliance. Adaptimmune's experience in cell therapy development and its strong scientific team are critical to its success in navigating the regulatory landscape. They also leverage strategic partnerships to gain expertise and resources in regulatory affairs.
How does Adaptimmune Therapeutics plc manage patent expiration risks?
Adaptimmune Therapeutics plc manages patent expiration risks through a multi-faceted approach. The company actively seeks to expand its intellectual property portfolio by filing new patent applications for its technologies and therapies. They also pursue strategies to extend the life of existing patents, such as developing new formulations or uses for their products. Furthermore, Adaptimmune monitors the competitive landscape and takes steps to protect its intellectual property rights against infringement. Their focus on innovation and continuous development of new technologies helps to mitigate the impact of patent expirations.
What are the key factors to evaluate for ADAP?
Adaptimmune Therapeutics plc (ADAP) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary SPEAR T-cell platform. Primary risk to monitor: Unfavorable clinical trial results could delay or halt the development of Adaptimmune's therapies. This is not financial advice.
How frequently does ADAP data refresh on this page?
ADAP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ADAP's recent stock price performance?
Recent price movement in Adaptimmune Therapeutics plc (ADAP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary SPEAR T-cell platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.